Replies to post #77012 on Avid Bioservices Inc (CDMO)

[Robert C Jonson]

The point that I am trying to make is that reported median PFS values tend to vary quite a bit;

And that's a good point, thanks. It illustrates why the FDA is not (I think) relying on ORR and PFS, but MOS to make their drug approval decisions. Since there appears to be such variation in these subjective measurements, I'm not sure why we still list them as endpoints in drug trials.

[geocappy1]

Let it go as it doesn't matter. MOS will tell the story. The point is you are on here always trying to put everything in the worst light. Bottom line is if this were Avastin reporting the control PFS would have been 4.5 and we would be talking about a 25% increase in PFS. Now why not look for the worst in some other company.